Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.65
-4.46 (-2.12%)
AAPL  265.00
+0.42 (0.16%)
AMD  198.03
-2.12 (-1.06%)
BAC  52.07
-0.99 (-1.87%)
GOOG  315.71
+0.81 (0.26%)
META  648.83
-6.83 (-1.04%)
MSFT  388.76
-8.47 (-2.13%)
NVDA  193.07
+3.25 (1.71%)
ORCL  141.91
-6.17 (-4.17%)
TSLA  403.24
-8.58 (-2.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.